The tirzepatide peptide sequence: science behind the structure

The misconception: tirzepatide is just a stronger GLP-1 medicine

The most common misunderstanding about tirzepatide is that it is simply a more potent version of semaglutide or another GLP-1 receptor agonist. It is not. The difference is written into its peptide sequence. Semaglutide's sequence is modelled on the natural GLP-1 hormone and activates one receptor. Tirzepatide's sequence is a different construction entirely, its backbone is closer to the native GIP hormone, with GLP-1 receptor affinity engineered in alongside it. Activating the GIP receptor produces effects on appetite, fat metabolism and insulin sensitivity that a GLP-1 agonist alone does not trigger in the same way. So when people ask why the trial results differ, the answer starts at the molecular level: two mechanisms, one molecule, one weekly injection. The relationship between GLP-1 and tirzepatide is worth understanding clearly if you are comparing treatment options, because they are related but not interchangeable ideas.

What the 39-amino-acid sequence actually does

Tirzepatide's peptide sequence contains 39 amino acids arranged in a precise order that determines which receptors it binds to and how tightly. The sequence includes a modification at one position (a C20 fatty-diacid chain attached via a linker) that anchors the molecule to albumin in the bloodstream after injection. That anchoring is what gives tirzepatide its roughly five-day half-life and makes once-weekly dosing viable. Without that structural feature, the peptide would be cleared from the body within hours, as natural GIP and GLP-1 are. You can read more about the individual amino acids in tirzepatide's sequence and how each contributes to its receptor activity. The NHS medicines information for tirzepatide covers the clinical effects at patient level, and the Mounjaro Summary of Product Characteristics on the eMC gives the full pharmacological detail for those who want to go deeper. What matters clinically is that the sequence is fixed and consistent: the molecule in a 2.5 mg starter pen is chemically identical to the one in a 15 mg pen; the prescriber-led titration changes how much is delivered, not what is delivered.

Why sequence matters for results, and what the trials showed

The dual-receptor activity encoded in tirzepatide's sequence translates into measurable clinical outcomes. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants taking the highest dose over 72 weeks achieved an average body-weight reduction of around 20–21%, with some analyses reaching approximately 22.5%. NICE's appraisal of tirzepatide (TA1026) reviewed this evidence and recommended it for eligible adults on the NHS. The SURMOUNT-5 head-to-head trial subsequently showed greater average weight reduction with tirzepatide than with semaglutide 2.4 mg over the same period. None of those outcomes are guaranteed for any individual (biology, starting weight, adherence and lifestyle all matter) but the sequence-level science is part of why the numbers look different from earlier medicines. If you are thinking about the cost of Mounjaro treatment relative to other options, the clinical evidence is a useful part of that comparison. A prescriber can help you weigh it against your own circumstances.

From molecular structure to the pen in your fridge

Tirzepatide as a medicine (sold in the UK as Mounjaro) is manufactured as a sterile aqueous solution, pre-filled into a KwikPen that delivers one dose per week. The peptide sequence discussed above is what sits inside that solution, alongside stabilisers and buffering agents, ready for subcutaneous injection into the abdomen, thigh or upper arm. When a pen is dispatched through a regulated pharmacy, it travels refrigerated and arrives the next working day via tracked courier in plain, unbranded packaging, the DPD notification lands on your phone before it reaches your door. The pen itself needs to stay refrigerated between 2 and 8 °C; the patient information leaflet that comes with it gives the exact window for room-temperature use, and that should always be the reference rather than any secondary source. For a broader grounding in how this medicine is used, the tirzepatide peptide overview and the Mounjaro treatment page both give context on dosing structure, eligibility and what to expect. Tirzepatide is a prescription-only medicine in the UK. The peptide sequence itself is a matter of pharmacology; whether it is the right treatment for you is a clinical decision made with a prescriber, not a chemistry question.